SeaStar Medical Holding Co. (NASDAQ:ICU) Sees Large Decrease in Short Interest

SeaStar Medical Holding Co. (NASDAQ:ICU) was the recipient of a large decrease in short interest in the month of February. As of February 15th, there was short interest totalling 300,900 shares, a decrease of 18.7% from the January 31st total of 370,200 shares. Approximately 3.6% of the company’s stock are short sold. Based on an average daily trading volume, of 423,600 shares, the days-to-cover ratio is presently 0.7 days.

Hedge Funds Weigh In On SeaStar Medical

An institutional investor recently raised its position in SeaStar Medical stock. Geode Capital Management LLC boosted its stake in shares of SeaStar Medical Holding Co. (NASDAQ:ICU) by 14.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 45,430 shares of the company’s stock after buying an additional 5,618 shares during the period. Geode Capital Management LLC owned approximately 1.02% of SeaStar Medical worth $88,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 1.69% of the company’s stock.

SeaStar Medical Price Performance

Shares of SeaStar Medical stock opened at $1.77 on Tuesday. SeaStar Medical has a 1 year low of $1.50 and a 1 year high of $27.50. The company has a 50-day moving average of $1.86 and a 200 day moving average of $3.09. The firm has a market cap of $7.90 million, a price-to-earnings ratio of -0.15 and a beta of -1.02.

SeaStar Medical Company Profile

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome.